Post-prandial carbohydrate modulation via gut-Indian perspective

Journal of Association of Physicians of India

Volumn 58, Issue 11, 2010, Pages 665-

  Joshi, Shashank R ^a  

^a GRANT MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE; ANTIDIABETIC AGENT; METFORMIN;

ASIAN; BLOOD; CHINA; EDITORIAL; GASTROINTESTINAL TRACT; GLUCOSE BLOOD LEVEL; HUMAN; INDIA; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE;

ACARBOSE; ALPHA-GLUCOSIDASES; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; CHINA; DIABETES MELLITUS, TYPE 2; GASTROINTESTINAL TRACT; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; METFORMIN; POSTPRANDIAL PERIOD;

EID: 78651249826     PISSN: 00045772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (6)

1. Joshi SR, Karne R. Pre-diabetes, dysglycaemia and early glucose intolerance and vascular health. J Assoc Physicians India 2007;55:829-31.
2. Laube H: Acarbose - An Update of its Therapeutic Use in Diabetes Treatment. Clin Drug Invest 2002;22:141-156.
3. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance - The STOP-NIDDM Trial. JAMA 2003;290:486-494
4. Hanefeld M,. Cagatay M, Petrowitsch T, Neuserb D, Petzinnab D, Rupp M: Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. European Heart Journal 2004;25:10-16.
5. Scarpella JHB, Howlett HCS: Metformin therapy and clinical Diabetes. Vasc Dis Res 2008;5157-67.
6. S. Jayaram, R. S. Hariharan, R. Madhavan, I. Periyandavar, S.S Samra: A Prospective, Parallel Group, Open-Labeled, Comparative, Multi-centric, Active Controlled Study to Evaluate the Safety, Tolerability and Benefits of Fixed Dose Combination of Acarbose and Metformin versus Metformin alone in Type 2 diabetes. J Assoc Physicians India 2010;48:679-687